22.03.2012 • NewsAstraZenecaTargacept

AstraZeneca Gives Up on Targacept Antidepressant

AstraZeneca has thrown in the towel on an experimental antidepressant targeting nicotine receptors after the drug licensed from Targacept failed in two remaining clinical trials, further thinning out its pipeline.

While the news had been widely expected, since two previous Phase III studies also missed their targets, it hit shares in Targacept hard and the stock tumbled.

Britain's second-biggest drugmaker will take an impairment charge of $50 million, representing the rest of the value of TC-5214 following a partial writedown late last year.

TC-5214 was initially deemed a potential multibillion-dollar-a-year seller as the first in a new class of medicines that work by calming neuronal nicotine receptors in the brain.

Company

Logo:

AstraZeneca

Byggrad 2/4
15185 Södertälje
Sweden

Company contact







Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read